Botswana vs Zambia: Statin use vs. average non-HDL cholesterol levels
Botswana
2.7
in 2018
Zambia
2.7
in 2018
Botswana rank
184th
Zambia rank
184th
Statin use vs. average non-HDL cholesterol levels over time
- Botswana
- Zambia
How they compare
Botswana currently reports 2.7 against 2.7 in Zambia, a difference of 0.
The two have swapped places 2 times across 39 shared years of data; in 1980 it was Zambia ahead.
Botswana ranks 184th and Zambia ranks 184th of 191 countries.
Across the 4 decades both report, Botswana averaged higher in 3 and Zambia in 1.
Head to head by decade
| Decade | Botswana | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.42 | 2.69 | 0.27 | Zambia |
| 1990s | 2.73 | 2.7 | 0.03 | Botswana |
| 2000s | 2.8 | 2.7 | 0.1 | Botswana |
| 2010s | 2.72 | 2.7 | 0.0222 | Botswana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Botswana or Zambia?
- Botswana, at 2.7 against 2.7 in Zambia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Botswana and Zambia?
- 0, with Botswana ahead.
- How many years of comparable data are there for Botswana and Zambia?
- 39 years are reported by both, from 1980 to 2018.
- How do Botswana and Zambia rank globally for statin use vs. average non-hdl cholesterol levels?
- Botswana ranks 184th and Zambia ranks 184th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.